Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Open Access
- 12 June 2011
- journal article
- review article
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2011, 1-13
- https://doi.org/10.1155/2011/542358
Abstract
Anaplastic thyroid cancer (ATC) is an uncommon malignancy of the thyroid. Only 1-2% of thyroid cancers are anaplastic, but the disease contributes to 14–50% of the mortality with a median survival of 3 to 5 months. Most patients diagnosed with this disease are 65 years of age or older. The incidence of anaplastic thyroid cancer is decreasing worldwide. Most patients present with a rapidly growing neck mass, dysphagia, or voice change. We performed a comprehensive literature search using PubMed focusing on the treatment of anaplastic thyroid cancer including historical review of treatment and outcomes and investigations of new agents and approaches. A total of sixteen chart review and retrospective studies and eleven prospective studies and/or clinical trials were reviewed. The current standard therapeutic approach is to consider the disease as systemic at time of diagnosis and pursue combined modality therapy incorporating cytoreductive surgical resection where feasible and/or chemoradiation either concurrently or sequentially. Doxorubicin is the most commonly used agent, with a response rate of 22%. Several new agents are currently under investigation. Referral of patients for participation in clinical trials is needed.Keywords
This publication has 105 references indexed in Scilit:
- Lower Incidence of Anaplastic Carcinoma After Higher Iodination of Salt in SloveniaThyroid®, 2010
- Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase–Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid CarcinomaMolecular Cancer Therapeutics, 2010
- Multimodality treatment for anaplastic thyroid carcinoma – Treatment outcome in 75 patientsRadiotherapy and Oncology, 2009
- A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with OutcomeThyroid®, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Trend in Thyroid Carcinoma Size, Age at Diagnosis, and Histology in a Retrospective Study of 500 Cases Diagnosed Over 20 YearsThyroid®, 2006
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996Cancer, 2000
- Clinical multidrug resistance in cancer: A multifactorial problemEuropean Journal of Cancer, 1996